Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 High incidence of HIV infections
3.2.1.2 Advances in therapeutic treatment options
3.2.1.3 Growing support through government initiatives and health programs
3.2.1.4 Favorable regulatory approvals
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of treatment
3.2.2.2 Concerns related to patient adherence and treatment continuity
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Gap analysis
3.6 Patent analysis
3.7 Technological landscape
3.8 Future market trends
3.9 Porter’s analysis
3.10 PESTEL analysis
Chapter 4 Competitive Landscape, 2024
4.1 Introduction
4.2 Company market share analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy outlook
Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 – 2034 ($ Mn)
5.1 Key trends
5.2 Branded drugs
5.3 Generic drugs
Chapter 6 Market Estimates and Forecast, By Drug Class, 2021 – 2034 ($ Mn)
6.1 Key trends
6.2 Nucleoside-analog reverse transcriptase inhibitors
6.3 Integrase inhibitors
6.4 Non-nucleoside reverse transcriptase inhibitors
6.5 Protease inhibitors
6.6 Entry and fusion inhibitors
6.7 Coreceptor antagonists
Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)
7.1 Key trends
7.2 Hospital pharmacies
7.3 Drugs stores and retail pharmacies
7.4 Online pharmacies
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Argentina
8.6 Middle East and Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
Chapter 9 Company Profiles
9.1 AbbVie
9.2 Aurobindo Pharma
9.3 Boehringer Ingelheim International GmbH
9.4 Bristol-Myers Squibb Company
9.5 Cipla
9.6 Dr. Reddy's Laboratories
9.7 F. Hoffmann-La Roche
9.8 Gilead Sciences
9.9 Hetero Drugs
9.10 Johnson & Johnson
9.11 Merck & Co
9.12 Mylan N.V. (Viatris)
9.13 Sun Pharmaceutical Industries
9.14 Teva Pharmaceutical Industries
9.15 ViiV Healthcare
